Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide
Susan Ahern
TL;DR
This case report discusses allodynia and dysesthesia as side effects of semaglutide and tirzepatide, which are used for diabetes and weight management.
Contribution
The paper presents a novel case of dysesthesia in a patient taking tirzepatide and adds to existing knowledge on semaglutide.
Findings
Allodynia and dysesthesia are reported as adverse effects of semaglutide and tirzepatide.
The side effects appear to be dose-dependent and may resolve after stopping the drug or over time.
Abstract
Semaglutide and tirzepatide are two commonly prescribed glucagon-like peptide-1 (GLP-1) and GLP-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonists used for the treatment of type 2 diabetes and chronic weight management. Allodynia and dysesthesia have been previously reported as effects of semaglutide. This case report adds to the literature on dysesthesia from semaglutide and presents a novel report in a patient taking tirzepatide. This adverse drug reaction occurs in both patients treated for type 2 diabetes and chronic weight management, appears to be dose dependent, and resolves with discontinuation of the drug and may resolve spontaneously after several weeks.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDiabetes Treatment and Management · Chronic Lymphocytic Leukemia Research · Colorectal Cancer Treatments and Studies